Genomma Lab InternacionalB de CVMEX:LABB +0.07%66 3-Year EBITDA Growth Rate is 7.10% as of Mar. 2026, which is 28% below its 10-year median of 9.90. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 814 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 52.95% on this metric.
During the past 12 months, Genomma Lab InternacionalB de CV's average EBITDA Per Share Growth Rate was -20.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genomma Lab InternacionalB de CV was 53.00% per year. The lowest was -1.10% per year. And the median was 9.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Genomma Lab InternacionalB de CV 3-Year EBITDA Growth Rate Related Terms
MEX:LABB vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's 3-Year EBITDA Growth Rate falls into.
Genomma Lab InternacionalB de CV 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.10% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a 3-Year EBITDA Growth Rate of 7.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genomma Lab InternacionalB de CV and its competitors. This is 28% below median its historical median of 9.90. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #431 out of 814 companies in the Drug Manufacturers industry, placing it in the top 52.9%.
Is Genomma Lab InternacionalB de CV's 3-Year EBITDA Growth Rate too high?
Genomma Lab InternacionalB de CV's current 3-Year EBITDA Growth Rate of 7.10% is 28% below median its 10-year median of 9.90. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Genomma Lab InternacionalB de CV's value of 7.10% is 20.2% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #431 out of 814 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #431 out of 814 companies for 3-Year EBITDA Growth Rate. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Genomma Lab InternacionalB de CV's value of 7.10% is 20.2% below this benchmark. While the company's 10-year median is 9.90 vs. the industry median of 8.90, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current 3-Year EBITDA Growth Rate of 7.10% is 20.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current 3-Year EBITDA Growth Rate is 7.10%, which is 28% below median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.67, compared to a current price of MXN15.34 — trading 13.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.10%, which is 28% below median its 10-year median of 9.90 and 20.2% below the Drug Manufacturers industry median of 8.90. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current 3-Year EBITDA Growth Rate is 7.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.34 is trading 13.2% below its estimated GF Value™ of MXN17.67.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
3-Year EBITDA Growth Rate: 7.10% (28% below median its 10-year median of 9.90)
GF Value™: MXN17.67 vs. price of MXN15.34 (13.2% below fair value)
Industry Position: 20.2% below the Drug Manufacturers median (#431 of 814)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 